Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
MUMBAI, India , July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma's continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.During FY2026, Piramal Pharma reported revenue from operations of ₹8,869 crore , supported by a diversified business model with 17 global development and manufacturing facilities, commercial presence across more than 100 countries. Approximately 66% of the Company's revenue was generated from regulated markets , reinforcing its strong global footprint.Ms. Nandini Piramal, Chairperson of Piramal Pharma Limited, said, "FY2026 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note across three businesses with improved execution and better visibility of future growth."Key Highlights from the report:
